Annotation Detail
Information
- Associated Genes
- TP53
- Associated Variants
-
TP53 DELETERIOUS MUTATION
TP53 DELETERIOUS MUTATION - Associated Disease
- leukemia
- Source Database
- CIViC Evidence
- Description
- Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2966
- Gene URL
- https://civic.genome.wustl.edu/links/genes/45
- Variant URL
- https://civic.genome.wustl.edu/links/variants/221
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Leukemia
- Evidence Direction
- Supports
- Drug
- RG7112
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 26459177
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| RG7112 | Resitance or Non-Reponse | true |